Poolbeg Pharma (LON:POLB) Hits New 1-Year Low – What’s Next?

Poolbeg Pharma PLC (LON:POLB) shares hit a new 52-week low during trading on Wednesday . The company traded as low as GBX 6.96 ($0.09) and last traded at GBX 7.14 ($0.09), with a volume of 463643 shares traded. The stock had previously closed at GBX 7.20 ($0.09).

Poolbeg Pharma Stock Performance

The stock has a market capitalization of £36.00 million, a P/E ratio of -735.00 and a beta of 2.11. The stock has a 50 day moving average of GBX 7.90 and a 200 day moving average of GBX 10.71.

About Poolbeg Pharma

Poolbeg Pharma plc operates as a biopharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an in­licensed first­in­class broad spectrum RNA­based immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis.